Lund-based SmiLe Inject Capital has recently invested 9 million SEK (approximately 0.8 million euros) in three pioneering life science startups: Uman Sense, Nygen Analytics, and Aligned Bio. Uman Sense, a spin-off from Lund University, is developing Stroke Alarm, a wristband that monitors patients at high risk for stroke, with 3 million SEK allocated to support its EU market launch. Nygen Analytics, specializing in cloud-based genomics data analytics, received 2 million SEK to enhance its technical capabilities and market positioning. Aligned Bio, focusing on nanowire-based biosensor technology for disease diagnostics and genome sequencing, secured 4 million SEK to scale production. SmiLe Inject Capital’s investments are aimed at propelling these companies toward rapid commercial success, with all three startups nearing significant milestones in their respective fields.
SmiLe Inject Capital contributes venture capital to SmiLe’s successful environment where life science companies commercialize their innovations to improve global health. There are a total of ten companies in SmiLe Inject Capital’s portfolio following the three most recent investments in the following companies:
Uman Sense, a MedTech innovation company and a spin-off from Lund University, has developed the groundbreaking Stroke Alarm, a wristband that continuously monitors patients at high risk for stroke. The technology, developed in collaboration with leading medical experts, aims to quickly alert and enable immediate care in the event of a suspected stroke. Stroke is one of the leading causes of permanent disability in adults and the second leading cause of death in the Western world. Uman Sense has secured a total investment of 12 million SEK, with SmiLe Inject Capital contributing 3 million SEK to support efficiency studies and the launch in the EU market.
Nygen Analytics is revolutionizing genomics data analytics with its cloud-based, LLM-driven platform, which significantly reduces the need for large computing capacity and expert knowledge. Nygen allows researchers in academia, biotech, and the pharmaceutical industry to quickly and efficiently analyse and gain deep insights from the massive amount of data generated when mapping genes from individual cells. The development of cell and gene therapies is a growing field in medical research. The goal is to eventually offer the pharmaceutical industry access to complete data ecosystem for drug development. SmiLe Inject Capital is contributing 2 million SEK to Nygen Analytics’ new share issue of a total of 7.5 million SEK to finance continued technical development and market positioning.
Aligned Bio is developing a new nanowire-based technology platform for biosensors. The company has chosen to apply the technology in two areas: disease diagnostics, such as cancer, and genome sequencing (mapping DNA). The technology can analyze longer DNA fragments and provides 10-100 times higher sensitivity in diagnostics compared to existing commercial sensors. It will also be indispensable in next-generation genome sequencing. The company has secured a funding round in which SmiLe Inject Capital is investing 4 million SEK to support continued technical development and scaling up production.
“SmiLe Inject has seen great potential for rapid commercial success in all these investments. All companies are close to market launch and have been working for a long time with strategic partners. Our hope is that their respective innovative technologies and strong teams have the potential to reach critical milestones to ensure commercial impact,” says Thomas Unt, CEO of SmiLe Inject Capital and business development coach at SmiLe.
Click to read more investor news.
Read the orginal article: https://arcticstartup.com/smile-inject-capital-invests-in-uman-sense-nygen-analytics-aligned-bio/
